- Paper Report
- Open Access
Autoimmunity to a ubiquitous glycoprotein targets the synovial joint
- Andrew Cope1
© Current Science Ltd 1999
- Published: 13 December 1999
- glycolytic enzyme
There is no compelling evidence either for or against the notion that chronic arthritis is driven by an autoimmune response to cartilage specific antigens. Accordingly, the identification of self antigens implicated in the development of spontaneous arthritis would be an important advance. In 1996, the Mathis and Benoist laboratory reported a spontaneous mouse model of arthritis in a T cell receptor (TCR) transgenic line, with features resembling rheumatoid arthritis (RA) in man (Kouskoff et al 1996, Cell 87: 811. Earlier this year the same group reported a series of elegant experiments which demonstrated distinct roles for T and B lymphocytes in the progression to disease, where T cells were critical during the early phase, despite evidence of multiple levels of tolerance, and B cells were important for the effector phase (Korganow et al 1999, Immunity 10: 451 [Paper report]). Importantly they demonstrated that arthritis could be transferred using a single intravenous injection of serum from arthritic mice. All the results pointed to a model in which transgenic T cells recognise a ubiquitous self antigen presented by non-obese diabetic (NOD) mouse MHC class II molecules in the periphery, and that sustained, systemic immune activation targeted synovial joints through processes involving activation of B cells and the production of high affinity arthritogenic autoantibodies. Identification of the specific autoantigen(s) responsible for the disease process was a priority. To identify the autoantigen(s) responsible for driving systemic autoimmunity in a spontaneous mouse model of rheumatoid arthritis.
Western blotting using serum from arthritic but not healthy mice identified an approximately 60 kDa protein in extracts of ankle, kidney and spleen. Purified IgG identified a similar band which was subsequently found by sequencing of tryptic peptide fragments to be glucose-6-phosphate isomerase (GPI), a glycoprotein of known molecular weight (62.6 kDa). By ELISA it was possible to demonstrate immunoreactivity in sera from arthritic mice to recombinant GST-GPI from as early as 3 weeks (around the time of arthritis onset), peaking at 8-10 weeks of age. Titres varied from 1:100 to 1:1,000,000. Significantly, immunoglobulin eluted from GST-GPI coupled matrices could transfer arthritis to recombination activating gene (RAG) deficient recipients following a single injection, with features typical of those observed in the original KRN TCR transgenic K/B x N mouse arthritis model. This confirmed that the target antigen was GPI, and that anti-GPI specific antibodies alone were arthritogenic in mice. NOD mouse antigen presenting cells (APCs) pulsed with GPI were capable of stimulating the original T cell hybridoma used to generate the KRN transgenic line, as well as resting TCR transegic T cells. Responses were comparable to those obtained following stimulation of the same T cells with bovine ribonuclease peptide 41-61 (the original specificity of KRN T cells) and I-Ak expressing APCs.
Sera from arthritic K/B x N or healthy control mice were used as "probes" for blotting and immunoprecipitation experiments using mouse tissue extracts as a source of putative autoantigen. Purified IgG fractions from sera of arthritic mice were used to affinity purify antigen, and to confirm the identity of the candidate autoantigen. Specific bands identified by blotting with these sera were excised prior to trypsin digestion, HPLC purification of peptide fragments and sequencing by Edman degradation. Recombinant fusion proteins of glutathione S-transferase (GST) coupled to autoantigen expressed in E. coli were used in blotting and ELISA experiments, and as a source of pure antigen to affinity purify immunoglobulin from sera of arthritic mice for use in arthritis induction experiments.